dihydroergotamine has been researched along with Leukemia, Myeloid, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Call, SG; Coarfa, C; Conneely, OM; Duren, RP; Freire, PR; Grimm, SL; Nguyen, L; Panigrahi, AK | 1 |
| Boudreaux, SP; Call, SG; Conneely, OM; Duren, RP; Freire, PR; Narayanan, P; Nguyen, L; Redell, MS | 1 |
2 other study(ies) available for dihydroergotamine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cellular Reprogramming; Dihydroergotamine; E1A-Associated p300 Protein; Enhancer Elements, Genetic; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Oncogenes; Proto-Oncogene Proteins c-myc; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Proliferation; Dihydroergotamine; Drug Delivery Systems; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Receptor Subfamily 4, Group A, Member 1; Transcriptome; Tumor Cells, Cultured; Vasoconstrictor Agents; Xenograft Model Antitumor Assays | 2019 |